两例转移性前列腺癌中KLK2-FGFR2融合基因的特征分析
在两例转移性前列腺癌患者中通过靶向RNA测序鉴定出KLK2-FGFR2融合基因,并在NIH3T3细胞中表达该融合蛋白进行功能表征。融合蛋白诱导形态学改变、促进迁移并激活FGFR下游信号,对多种FGFR抑制剂高度敏感。作者认为该融合是精准治疗的新靶点,建议对前列腺癌男性进行筛查。
要点
- 靶向RNA测序在两例转移性前列腺癌中鉴定出KLK2-FGFR2融合基因。
- KLK2-FGFR2融合蛋白在NIH3T3细胞中促进迁移并激活FGFR下游信号。
- 该融合蛋白对AZD-4547、BGJ398、JNJ-42756943、TAS-120和Ponatinib高度敏感,对Dovitinib不敏感。
核心结论
- KLK2-FGFR2融合是精准治疗的新靶点,作者认为应对前列腺癌男性进行筛查。
研究设计与样本
- 靶向RNA测序在两例转移性前列腺癌患者中鉴定KLK2-FGFR2融合基因,并用NIH3T3细胞转导表达该融合进行功能表征。
主要发现
- KLK2-FGFR2融合蛋白在NIH3T3细胞中诱导显著形态学改变,促进迁移增强并激活FGFR信号通路下游蛋白。
关键数值与推荐
- KLK2-FGFR2融合蛋白对选择性FGFR抑制剂AZD-4547、BGJ398、JNJ-42756943、不可逆抑制剂TAS-120及非选择性抑制剂Ponatinib高度敏感。
- KLK2-FGFR2融合对非选择性抑制剂Dovitinib未表现出敏感性。
临床怎么用
- 作者认为KLK2-FGFR2融合是精准治疗的新靶点,建议对前列腺癌男性进行筛查。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The fibroblast growth factor receptor (FGFR) signaling pathway is activated in multiple tumor types through gene amplifications, single base substitutions, or gene fusions. Multiple small molecule kinase inhibitors targeting FGFR are currently being evaluated in clinical trials for patients with FGFR chromosomal translocations. Patients with novel gene fusions involving FGFR may represent candidates for kinase inhibitors. METHODS: A targeted RNA-sequencing assay identified a KLK2-FGFR2 fusion gene in two patients with metastatic prostate cancer. NIH3T3 cells were transduced to express the KLK2-FGFR2 fusion. Migration assays, Western blots, and drug sensitivity assays were performed to functionally characterize the fusion. RESULTS: Expression of the KLK2-FGFR2 fusion protein in NIH3T3 cells induced a profound morphological change promoting enhanced migration and activation of downstream proteins in FGFR signaling pathways. The KLK2-FGFR2 fusion protein was determined to be highly sensitive to the selective FGFR inhibitors AZD-4547, BGJ398, JNJ-42756943, the irreversible inhibitor TAS-120, and the non-selective inhibitor Ponatinib. The KLK2-FGFR2 fusion did not exhibit sensitivity to the non-selective inhibitor Dovitinib. CONCLUSIONS: Importantly, the KLK2-FGFR2 fusion represents a novel target for precision therapies and should be screened for in men with prostate cancer.
引用
- Krook MA, Barker H, Chen HZ, et al. Characterization of a KLK2-FGFR2 fusion gene in two cases of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2019. PMID: 31043681. doi:10.1038/s41391-019-0145-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。